Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus

Desh Nepal; David Gazeley

doi:10.1093/rheumatology/kead416

Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus

Rheumatology (Oxford). 2023 Dec 1;62(12):3804-3810. doi: 10.1093/rheumatology/kead416.

Authors

Desh Nepal¹, David Gazeley¹

Affiliation

¹ Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

PMID: 37594751
DOI: 10.1093/rheumatology/kead416

Abstract

Interleukin-6 (IL-6) is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE.

Keywords: IL-6; IL-6 inhibition; SLE; sirukumab; tocilizumab.

Publication types

Review

MeSH terms

Animals
Cytokines
Humans
Interleukin-6*
Lupus Erythematosus, Systemic* / drug therapy
Mice
Severity of Illness Index

Substances

Interleukin-6
Cytokines